MedTrace Logo

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

NCT04506619 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2023-03-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.

Conditions

  • Retinopathy of Prematurity (ROP)
  • Intraventricular Hemorrhage
  • Bronchopulmonary Dysplasia
  • Chronic Lung Disease of Prematurity

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

  • Oak Hill Bio Ltd

    lead INDUSTRY

Eligibility

Min Age
12 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2022-08-05
Completion
2022-08-05
FDA Drug
Yes

Countries

  • United States
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04506619 on ClinicalTrials.gov